Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period
Public ClinicalTrials.gov record NCT04008784. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination Treatment of Crisaborole Ointment, 2% and a Concomitant Topical Corticosteroid Over a 8 Week Period
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is a single-center two arm, open label observational prospective study, that will evaluate the safety and efficacy of crisaborole ointment, 2% alone compared to a combination therapy of crisaborole and a topical corticosteroid (Triamcinolone Acetonide Ointment, 0.1%) over a 8 week period for the treatment of mild to moderate atopic dermatitis.
Study identification
- NCT ID
- NCT04008784
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 16 participants
Conditions and interventions
Conditions
Interventions
- Crisaborole 2% Topical Application Ointment [EUCRISA] Drug
- Triamcinolone Acetonide 0.1% Ointment Drug
Drug
Eligibility (public fields only)
- Age range
- 2 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 15, 2019
- Primary completion
- Jul 13, 2020
- Completion
- Sep 7, 2020
- Last update posted
- Apr 27, 2021
2019 – 2020
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research Center of the Carolinas | Charleston | South Carolina | 29407 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Atopic Dermatitis trials
Other public records listing Atopic Dermatitis. Sorted by last update posted; newest first. Not a recommendation.
- NCT04504955: CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness Recruiting
- NCT07783425: A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema Not yet recruiting
- NCT06718101: A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis Active, not recruiting
- NCT07643766: A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis Recruiting
- NCT07748169: An Observational Study of Patients With Dermatologic Disease Recruiting
- NCT07746427: Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04008784, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 27, 2021 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04008784 live on ClinicalTrials.gov.